Innovationen verändern die Welt: Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?

Research output: Contribution to journalArticleResearchpeer review

Authors

  • J. M. Graf Von Der Schulenburg
  • A. Kuhlmann
View graph of relations

Details

Translated title of the contributionInnovations change the world: What are the benefits of innovative drugs in the treatment of psychiatric disorders?
Original languageGerman
Pages (from-to)244-252
Number of pages9
JournalGesundheitsokonomie und Qualitatsmanagement
Volume18
Issue number5
Publication statusPublished - Oct 2013

Abstract

Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

Innovationen verändern die Welt: Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen? / Graf Von Der Schulenburg, J. M.; Kuhlmann, A.
In: Gesundheitsokonomie und Qualitatsmanagement, Vol. 18, No. 5, 10.2013, p. 244-252.

Research output: Contribution to journalArticleResearchpeer review

Graf Von Der Schulenburg, JM & Kuhlmann, A 2013, 'Innovationen verändern die Welt: Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?', Gesundheitsokonomie und Qualitatsmanagement, vol. 18, no. 5, pp. 244-252. https://doi.org/10.1055/s-0033-1355492
Graf Von Der Schulenburg, J. M., & Kuhlmann, A. (2013). Innovationen verändern die Welt: Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen? Gesundheitsokonomie und Qualitatsmanagement, 18(5), 244-252. https://doi.org/10.1055/s-0033-1355492
Graf Von Der Schulenburg JM, Kuhlmann A. Innovationen verändern die Welt: Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen? Gesundheitsokonomie und Qualitatsmanagement. 2013 Oct;18(5):244-252. doi: 10.1055/s-0033-1355492
Graf Von Der Schulenburg, J. M. ; Kuhlmann, A. / Innovationen verändern die Welt : Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?. In: Gesundheitsokonomie und Qualitatsmanagement. 2013 ; Vol. 18, No. 5. pp. 244-252.
Download
@article{c8753d47eb804497a53f11c0918d92d6,
title = "Innovationen ver{\"a}ndern die Welt: Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?",
abstract = "Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.",
keywords = "costs, innovation, psychiatric disorders, psychiatric drugs, regulation",
author = "{Graf Von Der Schulenburg}, {J. M.} and A. Kuhlmann",
year = "2013",
month = oct,
doi = "10.1055/s-0033-1355492",
language = "Deutsch",
volume = "18",
pages = "244--252",
number = "5",

}

Download

TY - JOUR

T1 - Innovationen verändern die Welt

T2 - Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?

AU - Graf Von Der Schulenburg, J. M.

AU - Kuhlmann, A.

PY - 2013/10

Y1 - 2013/10

N2 - Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.

AB - Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.

KW - costs

KW - innovation

KW - psychiatric disorders

KW - psychiatric drugs

KW - regulation

UR - http://www.scopus.com/inward/record.url?scp=84886872603&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1355492

DO - 10.1055/s-0033-1355492

M3 - Artikel

AN - SCOPUS:84886872603

VL - 18

SP - 244

EP - 252

JO - Gesundheitsokonomie und Qualitatsmanagement

JF - Gesundheitsokonomie und Qualitatsmanagement

SN - 1432-2625

IS - 5

ER -